Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' ("Opexa") lead personalized T-cell immunotherapy programs for Multiple Sclerosis ("MS") and Neuromyelitis Optica ("NMO").
Opexa's novel immunotherapy drug platform has the potential to improve the lives of people around the world suffering from autoimmune disorders. According to the National Multiple Sclerosis Society, it is estimated that more than 2.3 million people are affected by MS worldwide. There are also an estimated 4,000 people with NMO in the United States and a half a million people worldwide with the disease according to The Guthy-Jackson Charitable Foundation.
Cryoport's global distribution network will provide the necessary cryogenic logistics support between Opexa and its clinical sites.
Neil Warma, President and Chief Executive Officer of Opexa, commented, "We are pleased to be entering into this partnership with Cryoport and their best-in-class logistics solutions to ensure efficient and safe delivery of our T-cell products to clinical trial sites, and ultimately, to the patients. Cryoport, as with all our partners, plays an important role in the conduct and management of our clinical programs."
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are honored to support Opexa in their efforts to develop cutting edge immunotherapy treatments for the significant, unmet need of patients with Multiple Sclerosis and Neuromyelitis Optica. Working with Opexa to help advance their clinical programs is indeed exciting. We look forward to providing them with our superior service and offerings to help them move closer to managing these debilitating diseases."
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery